Suraksha Diagnostic's revenue grows 20%. Profit doesn't follow.
Revenue hit ₹300.68 cr in FY26, up 20.7%. Profit after tax grew just 1.9%. The earnings lag is the story.
— 5 earlier stories on Suraksha Diagnostic Ltd. →What's new
- FY26 standalone revenue from operations grew 20.7% to ₹300.68 cr.
- Profit after tax rose just 1.9% to ₹34.06 cr, with growth lagging far behind the top line.
- Board recommended a ₹0.50 per share dividend, up from zero a year ago on a standalone basis.
Why this matters
Suraksha is growing revenue at a decent clip, but the earnings follow-through is weak. A 1.9% profit increase on 20.7% revenue growth means costs expanded almost as fast as sales, leaving little for the bottom line. The ₹0.50 dividend is nominal.
What we're watching
- FY27 margin trajectory — whether cost growth can be reined in as revenue scales.
- Outcome of the step-down subsidiary dispute mentioned in disclosures.
- Any update on the Fetomat Wellness acquisition integration.
The full read
Suraksha Diagnostic's top line is growing. Its bottom line is not. The company grew standalone revenue by 20.7% in FY26 to ₹300.68 crore. Profit after tax rose just 1.9% to ₹34.06 crore. That margin squeeze is the headline. The board rewarded shareholders with a dividend of ₹0.50 per share, the first on a standalone basis in two years. It's a token. The filing also touches on the Fetomat Wellness acquisition and a step-down subsidiary dispute, both previously disclosed. The numbers themselves were anticipated. The new data point is how little of the revenue growth flowed to profit.
Questions answered
- How much did Suraksha's revenue and profit grow in FY26?
- Standalone revenue from operations grew 20.7% to ₹300.68 crore for the full year. Profit after tax rose just 1.9% to ₹34.06 crore.
- What dividend did the board declare?
- The board recommended a dividend of ₹0.50 per equity share. On a standalone basis, Suraksha paid no dividend in the prior year, so this is a new payout, albeit a small one.
- Why did profit barely grow despite strong revenue growth?
- The filing does not provide a detailed cost breakdown, but the 1.9% PAT growth on 20.7% revenue growth indicates a significant portion of the top-line expansion was absorbed by higher operating expenses.
- Are there any other material developments in the filing?
- The results are accompanied by disclosures on the Fetomat Wellness acquisition, a step-down subsidiary dispute, and routine auditor appointments. The audit opinion was unmodified.
Suraksha Diagnostic Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on SURAKSHA →- 21 May 2026 · 7:07 PM IST Suraksha Diagnostic's revenue grows 20%. Profit doesn't follow.
- 40d ago Suraksha Diagnostic transcript confirms previously issued FY27 guidance
- 45d ago Suraksha Diagnostic cools growth targets to 15% for FY27
- 46d ago Suraksha's revenue grew 22.5%, but profit fell 14% in Q4.
- 46d ago Suraksha Diagnostic revenue lifts 21% as margins tighten